

Francesco Sica

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5867973/publications.pdf>

Version: 2024-02-01

11
papers

520
citations

1039880

9
h-index

1281743

11
g-index

11
all docs

11
docs citations

11
times ranked

1037
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1498. | 4.5 | 262 |
| 2 | Obesity worsens central inflammation and disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1237-1246. | 1.4 | 72 |
| 3 | Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. <i>Journal of Neurology</i> , 2018, 265, 828-835. | 1.8 | 45 |
| 4 | Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?. <i>Neurochemistry International</i> , 2014, 79, 44-56. | 1.9 | 31 |
| 5 | Interleukin-6 Disrupts Synaptic Plasticity and Impairs Tissue Damage Compensation in Multiple Sclerosis. <i>Neurorehabilitation and Neural Repair</i> , 2019, 33, 825-835. | 1.4 | 26 |
| 6 | Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430. | 0.9 | 23 |
| 7 | Fingolimod Immune Effects Beyond Its Sequestration Ability. <i>Neurology and Therapy</i> , 2019, 8, 231-240. | 1.4 | 22 |
| 8 | Sundowning Syndrome: A Possible Marker of Frailty in Alzheimer's Disease?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 525-528. | 0.8 | 15 |
| 9 | Practice-dependent motor cortex plasticity is reduced in non-disabled multiple sclerosis patients. <i>Clinical Neurophysiology</i> , 2020, 131, 566-573. | 0.7 | 13 |
| 10 | Electroencephalography and Dementia: A Literature Review and Future Perspectives. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 512-519. | 0.8 | 6 |
| 11 | Fingolimod reduces the clinical expression of active demyelinating lesions in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 215-219. | 0.9 | 5 |